Hair loss can have significant negative impact on the self-esteem and quality of life of the men an women affected. According to The Washington Post, American hair loss sufferers spend more than 3.5 billion dollars a year in an attempt to treat their hair loss. Unfortunately, 99% of all products being marketed in the less than ethical hair loss treatment industry are completely ineffective for the majority of those who use them.
It is refreshing that in a field that is riddled with sham products there is now one that has all the science and research behind it and it is of medical grade quality.
Biohair X® has been formulated by a licensed physician specialized in hair loss and treatment since 1993 who is renowned in his field and compounded by a certified USA pharmaceutical company, Every active ingredient in BioHair X® has been extensively studied in both animal and human studies and proven to be effective. The research scientist at BioLife have specifically designed BioHair X® to stop your hair loss and re-grow your hair regardless of whether you have alopecia androgenetica or alopecia areata.
3 Proven Active Ingredients
Tofacitinib - Janus Kinase (JAK) inhibitors are FDA approved drugs for oral use to treat Rheumatoid Arthritis. In recent animal and human studies it has been found that JAK modulators reduce peri-follicular inflammation and stimulate your hair follicles to jump back into growth phase. Once the follicle is stimulated to grow hair again the hair resumes its normal growth pattern and grows about 1cm every month. With this treatment your hairs reverse the steps to baldness leading you back to a full head of hair. In some animal studies hair regrowth occurred in 10 days! Now in phase 2 clinical trials for hair loss, the results have been incredibly promising for both types of alopecia: areata and androgenetica. Here are just some of the actual results from real patients:
Since these landmark animal studies a study of 90 adults with severe alopecia areata (at least 40% scalp hair loss) who were treated for 4 to 18 months with tofacitinib, 20% had nearly total hair regrowth, 58% had more than 50% regrowth, and 77% had some regrowth (J Am Acad Dermatol. 2017;76:22-28).
And in a retrospective study of adolescents with severe alopecia who were treated with tofacitinib, the median change in Severity of Alopecia Tool (SALT) score was 93% (mean, 61%) in nine of the 13 study participants after an average of 6.5 months of treatment (J Am Acad Dermatol. 2017;76:29-32). Tofacitinib was well tolerated, and there were no serious adverse effects, reported Brett King, MD, PhD, from Yale University in New Haven, Connecticut, who has been at the forefront of research in this area.
JAK are relatively safe and can produce a full head of hair in patients with moderate to severe alopecia areata (AA), although patients tend to shed hair after stopping treatment, Julian Mackay-Wiggan, MD, said at the annual meeting of the Society for Investigative Dermatology.
"At this point, there are 17 publications in the literature, from clinical trials to case reports, looking at JAK [Janus kinase] inhibitors in patients with alopecia areata," said Dr. Mackay-Wiggan of the department of dermatology, Columbia University, New York, where she specializes in hair disorders. "Pretty much all report very positive findings. It definitely appears that Janus kinase inhibitors can play a very significant role in treatment."
There's a reason the drugs work specifically in those with AA. In alopecia areata, the body's immune system attacks the hair follicle believing it to be a foreign invader. The JAK inhibitor blocks the attack message to the immune system allowing the hair to regrow. And because the hair follicle was not damaged, the hair grows as it should, as long as the patient takes the medication. This is unlike male- or female-pattern baldness, in which the hair follicle atrophies and stops growing hair.
Bimatoprost - This Prostamide is the active ingredient in Latisse®, FDA approved to grow longer thicker lashes. To date the Phase 1 and 2 clinical trial findings have reported that Bimatoprost 1% and Bimatoprost 3% BID both result in slightly superior hair growth in comparison to Minoxidil 5%, based on an “Expert Panel Review” and based on an “Investigator Global Assessment.” It seems to work by making follicles stay in the anagen (growing) phase for a longer period of time, which increases the growing time. This also means new hair forms quicker, and old hair falls out slower, so there are more visible hairs coming out at any time, which gives you denser hair.
Melatonin - Research published in the International Journal of Trichology in 2012 found that the antiandrogen and antioxidant properties of the hormone melatonin could be made into a topical solution for the treatment of early stage androgenetic alopecia, or common male and female pattern baldness. Four different study designs observed that daily application of the melatonin solution to the scalp reduced hair loss and caused new hair growth.
Melatonin (N-acetyl-5-methoxy-tryptamine) is a possible candidate to counteract the oxidative stress associated with general hair loss as well as AGA because of the strong anti-oxidant properties that have been described for this substance. It is most notable for its protective and anti-apoptotic effects, which can ensure the functional integrity of non-neoplastic cells, due to its strong anti-oxidant properties and ability to actively capture free radicals.
Like human skin, human hair follicles have been shown to synthesize melatonin and express melatonin eceptors, and an influence on hair growth cycles has been observed. In human anagen hair follicles cultivated in vitro at a concentration of 30 μM melatonin results in a significantly faster rate of hair follicle growth in comparison to the culture medium alone. Additionally, a Melatonin antagonist, 4-phenyl-2-propionamidotetralin, suppressed hair growth. Lastly, the regulation of melatonin receptors during the course of the hair cycle phases has already been shown, at least in the mouse model.
A double-blind, placebo-controlled pilot study a topical treatment a melatonin-alcohol solution in women with AGA and diffuse alopecia resulted in a significant increase in detectable anagen hairs in the occipital and frontal areas after only six months compared with placebo. From January 2003 to October 2006 the melatonin solution was subjected to five rounds of testing, each with a different study design.The research showed that:
- Topical Melatonin was safe and well tolerated.
- A significant reduction in severity of hair loss in 30 patients with early hair loss after 30 days of treatment, with a further significant drop after 90 days.
- An objective open-label, clinically controlled study involving 35 men with androgenetic alopecia. In this study, researchers used TrichoScan, a sensitive software and hardware package that uses epiluminescence to measure hair loss. Hair density was found to increase in over half of the subjects. The average increase in density was 29% after three months and 41% at six months.
- A large-scale, open-label, multi-center study involving 1891 female and male patients with early stage androgenetic alopecia found that after 90 days of treatment, the proportion of patients with a positive hair pull test (which indicates ongoing hair loss) fell from 61.6% to 7.8%. Negative hair pull tests, which indicate no hair loss, rose from 12.2% to 61.5% in the same period. Using standardized examination forms, investigators found significantly reduced hair loss in two-thirds of patients. New hair growth was measured in 22.5% of patients.
Once again Dr. Setari’s extensive research is put to practical applications with BioHair X® which includes topical Melatonin; a proven, safe, and natural hair loss treatment that other hair products don’t even address.